Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients

Transplant Infectious Disease

Volumn 12, Issue 6, 2010, Pages 489-496

  Avery, R K ^a   Marty, F M ^b   Strasfeld, L ^c   Lee, I ^d   Arrieta, A ^e   Chou, S ^f   Tatarowicz, W ^g   Villano, S ^g  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^f PORTLAND VA MEDICAL CENTER   (United States)

^g ViroPharma Incorporated   (United States)

Author keywords

Antiviral resistance; Cytomegalovirus; Ganciclovir; Maribavir

Indexed keywords

ANTINEOPLASTIC AGENT; BENZIMIDAVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; LEFLUNOMIDE; VIRUS DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS RETINITIS; DUODENITIS; FEMALE; FOOD AND DRUG ADMINISTRATION; GENOTYPE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; PHENOTYPE; PHYSICIAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; VIREMIA; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ORGAN TRANSPLANTATION; RIBONUCLEOSIDES; TREATMENT OUTCOME;

EID: 78650157268     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00550.x     Document Type: Article

References (21)

1. Dummer S. Controlling the troll: management of cytomegalovirus infection after transplantation. Ann Intern Med 2005; 143 (12): 913-914.
2. Snydman DR. Persistent clinical impact of cytomegalovirus in organ transplantation. Clin Infect Dis 2008; 47 (7): 883-884.
3. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356 (9230): 645-649.
4. Drew WL, Paya CV, Emery V. Cytomegalovirus (CMV) resistance to antivirals. Am J Transplant 2001; 1 (4): 307-312.
5. Isada CM, Yen-Lieberman B, Lurain NS, et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis 2002; 4 (4): 189-194.
6. Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002; 34 (10): 1337-1341.
7. Avery RK. Update in management of ganciclovir-resistant cytomegalovirus infection. Curr Opin Infect Dis 2008; 21 (4): 433-437.
8. Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002; 46 (8): 2365-2372.
9. Evers DL, Komazin G, Ptak RG, et al. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob Agents Chemother 2004; 48 (10): 3918-3927.
10. Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006; 37 (2): 124-127.
11. Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003; 47 (4): 1334-1342.
12. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008; 111 (11): 5403-5410.
13. Marty F, Boeckh M, Ljungman P, et al. Prophylaxis against cytomegalovirus with oral maribavir in allogeneic stem cell transplant recipients: results of a phase 3 randomized, double-blind, placebo-controlled trial. Paper presented at 35th annual meeting of the European Group for Blood and Marrow Transplantation, 2009; Goteborg, Sweden. Bone Marrow Transplant 2009; 43 (Suppl 1): S59.
14. Strasfeld L, Lee I, Tatarowicz W, Villano S, Chou S. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis 2010; 202 (1): 104-108.
15. Marfori JE, Exner MM, Marousek GI, Chou S, Drew WL. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol 2007; 38 (2): 120-125.
16. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185 (1): 20-27.
17. Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 2007; 45 (4): 439-447.
18. Ljungman P, Engelhard D, Link H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 1992; 14 (4): 831-835.
19. Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004; 34 (12): 1071-1075.
20. Levi ME, Mandava N, Chan LK, Weinberg A, Olson JL. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8 (1): 38-43.
21. Drew WL. Ganciclovir resistance: a matter of time and titre. Lancet 2000; 356 (9230): 609-610.